Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07525076 · ClinicalTrials.gov registry record · NA

Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department

A NA study, sponsored by The University of Texas Health Science Center, Houston.

Not yet
Registry status
NA
Development phase
1,400
Enrollment target

NCT07525076: Clinical Trial NA study, sponsored by The University of Texas Health Science Center, Houston.

NCT07525076 is a NA study that has not yet begun recruiting, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 1,400 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07525076, a NA study, has not yet begun recruiting, sponsored by The University of Texas Health Science Center, Houston.

NOT YET RECRUITING
Registry status
NA
Development phase
1,400 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate infection detection and treatment initiation rates for syphilis and HIV before and after integration of the Chembio DPP® HIV-Syphilis rapid POC test into an ongoing Emergency Department (ED) testing program and to determine whether dual rapid testing improves early initiation of HIV therapy in pregnant patients with newly identified HIV infection.

Interventions

  • DIAGNOSTIC_TEST Chembio HIV/Syphilis rapid Point of Care (POC) test
  • DIAGNOSTIC_TEST Laboratory-based HIV and syphilis testing

Trial Details

FieldValue
Enrollment Target 1,400 participants
Start Date 2026-04-15
Est. Completion 2028-05-31
Phase NA

What is known before NCT07525076 opens enrollment

NCT07525076 is an interventional study that assigns participants to a tested intervention. Its 1,400 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.

The record links to 0 conditions, and to 2 interventions - of which Chembio HIV/Syphilis rapid Point of Care (POC) test is the first listed.

NCT07525076 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07525076 about?

NCT07525076 is a clinical study titled "Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department". The purpose of this study is to evaluate infection detection and treatment initiation rates for syphilis and HIV before and after integration of the Chembio DPP® HIV-Syphilis rapid POC test into an ongoing Emergency Department (ED) testing program and to determine whether dual rapid testing improves...

What is the current status of trial NCT07525076?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2026-04-15. Estimated completion is 2028-05-31.

What interventions are being tested in trial NCT07525076?

The interventions under investigation include: Chembio HIV/Syphilis rapid Point of Care (POC) test (DIAGNOSTIC_TEST), Laboratory-based HIV and syphilis testing (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT07525076?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07525076's enrollment target sits among peer trials

1,400 71st of 2000 higher than 1,928 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02205762 · 1,400 participants · Phase 2

    LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

  • NCT02445222 · 1,400 participants · Phase 3

    CAR-T Long Term Follow Up (LTFU) Study

  • NCT03145077 · 1,400 participants · NA

    Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body

  • NCT04250857 · 1,400 participants

    HeartStart FRx Defibrillator Event Registry

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07525076, the US trial registry maintained by the National Library of Medicine. NCT07525076 (large enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.